Hostname: page-component-74656f9884-kv2lp Total loading time: 0 Render date: 2026-11-06T12:37:19.868Z Has data issue: false hasContentIssue false

Alcohol sclerotherapy of human immunodeficiency virus related parotid lymphoepithelial cysts

Published online by Cambridge University Press:  01 July 2008

E Meyer
Affiliation:
Division of Otolaryngology, University of Cape Town Faculty of Health Sciences, South Africa
D E Lubbe*
Affiliation:
Division of Otolaryngology, University of Cape Town Faculty of Health Sciences, South Africa
J J Fagan
Affiliation:
Division of Otolaryngology, University of Cape Town Faculty of Health Sciences, South Africa
*
Address for correspondence: Dr D E Lubbe, Division of Otolaryngology, University of Cape Town Faculty of Health Sciences, H-53 OMB, Groote Schuur Hospital, Observatory, Cape Town 7925, South Africa. Fax: +27 21 448 8865 E-mail: delubbe@kingsley.co.za
Rights & Permissions [Opens in a new window]

Abstract

Objective:

The aim of the study was to determine the effectiveness of alcohol sclerotherapy in patients with human immunodeficiency virus related salivary gland disease.

Study design:

Prospective study investigating the effectiveness of alcohol as a sclerosing agent.

Setting:

Tertiary referral hospital.

Patients:

Eleven human immunodeficiency virus positive patients with benign lymphoepithelial cysts were included in the study, from July 2005 to September 2006.

Interventions:

Alcohol sclerotherapy was performed under local anaesthesia, with alcohol infiltrated into the benign lymphoepithelial cysts.

Results:

Alcohol injection sclerotherapy proved to be an effective, simple, cheap, ambulatory procedure for patients who did not qualify for antiretroviral treatment.

Information

Type
Main Articles
Copyright
Copyright © JLO (1984) Limited 2008
Figure 0

Table I Key diagnostic points for HIV-related benign lymphoepithelial cysts

Figure 1

Table II Patient data

Figure 2

Table III Follow-up statistics

Figure 3

Fig. 1 Pre-sclerotherapy human immunodeficiency virus related salivary gland disease.

Figure 4

Fig. 2 Post-sclerotherapy result.